Bush Names New Director of NIH

Publication
Article
OncologyONCOLOGY Vol 16 No 5
Volume 16
Issue 5

Elias Zerhouni, MD, nominated by President Bush to the position of director of the National Institutes of Health, is a leading researcher in cardiovascular imaging.

Elias Zerhouni, MD, nominated by PresidentBush to the position of director of the National Institutes of Health, is aleading researcher in cardiovascular imaging. 

Zerhouni also has a formidablecancer background, having conducted substantial National Cancer Institute-fundedresearch early in his career on diagnostic imaging of lung, prostate,colorectal, and pancreatic cancers. Moreover, he is a member of the NCI Board ofScientific Advisors, and many of the 157 journal articles he has authored orcoauthored focus on cancer topics. In addition, Zerhouni is Martin DonnerProfessor and chairman of the Russell H. Morgan department of radiology at JohnsHopkins Medical School, as well as executive vice dean of the medical school. 

His background prompted Martin D. Abeloff, director of the Sidney KimmelComprehensive Cancer Center at Johns Hopkins and a former president of theAmerican Society of Clinical Oncology, to say, "Dr. Zerhouni is animpressive clinical scientist and administrator."

Bush chose Zerhouni not only for the quality and depth of hisresearch experience, but also because of his political acceptability: Zerhouniis reported to oppose research on cloned human embryos, which is in line withthe Bush administration’s position. Democrats, who control the Senate, whichmust confirm Zerhouni, favor a bill presented by Sen. Dianne Feinstein(D-Calif) that bans human cloning but allows research involving nucleartransplantation to produce stem cells. Sen. Edward Kennedy (D-Mass),chairman of the Senate Health, Education, Labor, and Pensions Committee,commented positively on Zerhouni. Jim Manley, Kennedy’s spokesman, saysZerhouni has "impressive credentials and a distinguished record at JohnsHopkins." He adds, "We will review his record carefully."

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Related Content